CL2011000806A1 - Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. - Google Patents
Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.Info
- Publication number
- CL2011000806A1 CL2011000806A1 CL2011000806A CL2011000806A CL2011000806A1 CL 2011000806 A1 CL2011000806 A1 CL 2011000806A1 CL 2011000806 A CL2011000806 A CL 2011000806A CL 2011000806 A CL2011000806 A CL 2011000806A CL 2011000806 A1 CL2011000806 A1 CL 2011000806A1
- Authority
- CL
- Chile
- Prior art keywords
- dabigatran etexilate
- stroke
- atrial fibrillation
- prevention
- patients suffering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Uso de etexilato de dabigatran para la prevención del ictus en pacientes que padecen fibrilación auricular, en el que el paciente no tiene factores de riesgo para acontecimientos hemorrágicos mayores; y medicamento que comprende 150 mg de etexilato de dabigatran.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11341308P | 2008-11-11 | 2008-11-11 | |
US23755909P | 2009-08-27 | 2009-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000806A1 true CL2011000806A1 (es) | 2011-11-11 |
Family
ID=41463075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000806A CL2011000806A1 (es) | 2008-11-11 | 2011-04-12 | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. |
Country Status (21)
Country | Link |
---|---|
US (3) | US20110269799A1 (es) |
EP (1) | EP2355823A1 (es) |
JP (1) | JP2013510073A (es) |
KR (1) | KR20110082564A (es) |
CN (2) | CN103463083A (es) |
AR (1) | AR074107A1 (es) |
AU (1) | AU2009315730A1 (es) |
BR (1) | BRPI0921354A2 (es) |
CA (1) | CA2738884A1 (es) |
CL (1) | CL2011000806A1 (es) |
CO (1) | CO6382133A2 (es) |
EA (1) | EA201100755A1 (es) |
EC (1) | ECSP11011029A (es) |
IL (1) | IL211853A0 (es) |
MA (1) | MA32785B1 (es) |
MX (1) | MX2011004796A (es) |
NZ (1) | NZ592615A (es) |
PE (1) | PE20110432A1 (es) |
TN (1) | TN2011000227A1 (es) |
TW (1) | TW201031651A (es) |
WO (1) | WO2010055022A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201100756A1 (ru) | 2008-11-11 | 2011-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином |
HUE032862T2 (en) * | 2011-07-25 | 2017-11-28 | Dritte Patentportfolio Beteili | Dabigatran amidoxime acid esters as prodrug forms and their use as medicaments |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
CN108254216B (zh) * | 2018-03-15 | 2021-04-27 | 攀钢集团西昌钢钒有限公司 | 一种高炉槽的矿料取样方法、装置及可读存储介质 |
WO2020180489A1 (en) * | 2019-03-06 | 2020-09-10 | University Of Rochester | Anticoagulant compositions and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
WO2008009638A2 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors in the cardiovascular field |
-
2009
- 2009-11-10 KR KR1020117010632A patent/KR20110082564A/ko not_active Application Discontinuation
- 2009-11-10 BR BRPI0921354A patent/BRPI0921354A2/pt not_active IP Right Cessation
- 2009-11-10 EP EP09755873A patent/EP2355823A1/en not_active Withdrawn
- 2009-11-10 NZ NZ592615A patent/NZ592615A/xx not_active IP Right Cessation
- 2009-11-10 EA EA201100755A patent/EA201100755A1/ru unknown
- 2009-11-10 AU AU2009315730A patent/AU2009315730A1/en not_active Abandoned
- 2009-11-10 AR ARP090104347A patent/AR074107A1/es unknown
- 2009-11-10 JP JP2011535125A patent/JP2013510073A/ja active Pending
- 2009-11-10 PE PE2011001003A patent/PE20110432A1/es not_active Application Discontinuation
- 2009-11-10 MX MX2011004796A patent/MX2011004796A/es not_active Application Discontinuation
- 2009-11-10 US US13/128,460 patent/US20110269799A1/en not_active Abandoned
- 2009-11-10 TW TW098138140A patent/TW201031651A/zh unknown
- 2009-11-10 CN CN2013102966233A patent/CN103463083A/zh active Pending
- 2009-11-10 WO PCT/EP2009/064874 patent/WO2010055022A1/en active Application Filing
- 2009-11-10 CA CA2738884A patent/CA2738884A1/en not_active Abandoned
- 2009-11-10 CN CN2009801448169A patent/CN102209546A/zh active Pending
-
2010
- 2010-06-17 US US12/817,369 patent/US20100322870A1/en not_active Abandoned
-
2011
- 2011-03-22 IL IL211853A patent/IL211853A0/en unknown
- 2011-04-12 CL CL2011000806A patent/CL2011000806A1/es unknown
- 2011-05-04 EC EC2011011029A patent/ECSP11011029A/es unknown
- 2011-05-10 TN TN2011000227A patent/TN2011000227A1/fr unknown
- 2011-05-11 MA MA33833A patent/MA32785B1/fr unknown
- 2011-05-11 CO CO11058058A patent/CO6382133A2/es not_active Application Discontinuation
-
2012
- 2012-07-06 US US13/543,080 patent/US20120277269A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2010055022A1 (en) | 2010-05-20 |
EP2355823A1 (en) | 2011-08-17 |
US20110269799A1 (en) | 2011-11-03 |
AR074107A1 (es) | 2010-12-22 |
MA32785B1 (fr) | 2011-11-01 |
ECSP11011029A (es) | 2011-06-30 |
TN2011000227A1 (en) | 2012-12-17 |
KR20110082564A (ko) | 2011-07-19 |
IL211853A0 (en) | 2011-06-30 |
PE20110432A1 (es) | 2011-07-16 |
EA201100755A1 (ru) | 2011-12-30 |
CN102209546A (zh) | 2011-10-05 |
JP2013510073A (ja) | 2013-03-21 |
CA2738884A1 (en) | 2010-05-20 |
MX2011004796A (es) | 2011-05-30 |
NZ592615A (en) | 2013-06-28 |
BRPI0921354A2 (pt) | 2019-09-24 |
TW201031651A (en) | 2010-09-01 |
US20120277269A1 (en) | 2012-11-01 |
AU2009315730A1 (en) | 2010-05-20 |
US20100322870A1 (en) | 2010-12-23 |
CN103463083A (zh) | 2013-12-25 |
CO6382133A2 (es) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
RS53056B (en) | PHARMACEUTICAL PREPARATION CONTAINING (1S) -1,5-ANHYDRO-1- [5- (4-ETHOXYBENZYL) -2-METHOXY-4-METHYLPHENYL] -1-THI-D-GLUCITOL AND METFORMIN AND ITS USE IN THE TREATMENT OF DIABETES | |
BRPI0908124A2 (pt) | Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença | |
ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
AR065392A1 (es) | Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
CL2010001123A1 (es) | Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07). | |
CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
CO6311083A2 (es) | 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
ECSP10010567A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona | |
CO6430497A2 (es) | Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento | |
CR20170404A (es) | Usos farmacéuticos novedosos | |
BR112015012497A2 (pt) | combinações farmacêuticas |